SOTIO Expands its Antibody-Drug Conjugate Pipeline with Exclusive Collaboration and License Agreement with LegoChem Biosciences

Company contact:? ? | Media contact: |
Richard Kapsa?? | Michael Tattory |
Head of Communication?? | LifeSci Communications |
T:?(+420) 224?174?448 | T:?+1 609-802-6265 |
M: (+420) 603?280?971 | mtattory@lifescicomms.com |
kapsa@sotio.com |
About SOTIO Biotech
SOTIO Biotech is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. The robust SOTIO clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, SOT101, currently being tested phase II clinical trials. Three programs will enter phase I clinical testing within the next 12 months, including SOT201, an IL-15-based immunocytokine, BOXR1030, a GPC3-targeted CAR-T based on proprietary technology designed to improve on the efficacy of CAR-T therapies in the tumor microenvironment and SOT102, a next generation Claudin18.2-targeted antibody-drug conjugate (ADC). SOTIO is a member of the PPF Group. For more information, please visit the company?s website at?www.sotio.com. SOTIO is a registered trademark of SOTIO a.s. in selected countries.